On Thursday, Chimerix Inc (NASDAQ:CMRX)’s shares inclined 0.62% to $40.43.
Chimerix Inc (CMRX) declared the pricing of an underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $39.75 per share. The gross proceeds to Chimerix from this offering, before deducting underwriting discounts and commissions and other offering expenses payable by Chimerix, are predictable to be about $150 million. The offering is predictable to close on or about June 16, 2015, subject to customary closing conditions. Chimerix anticipates using the net proceeds from the offering to fund its research and development efforts and for general corporate purposes, counting working capital.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds comprise brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, in addition to to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections.
Advaxis, Inc. (NASDAQ:ADXS)’s shares gained 2.56% to $24.46.
Advaxis, Inc. (ADXS) declared that it has designated Fred J. Frullo as Vice President, Regulatory Affairs. With more than 20 years of experience in the biopharmaceutical industry, Mr. Frullo is well versed in the development of global regulatory strategies for the supervision, review and assembly of pharmaceutical product submission and coordination with global health authorities to obtain approvals.
As Vice President, Regulatory Affairs, Mr. Frullo will oversee regulatory submissions for the company’s Lm-LLO cancer immunotherapy clinical programs, counting ADXS-HPV, ADXS-PSA and ADXS-HER2, in addition to combination studies involving complementary immunotherapy technologies. Mr. Frullo will lead the development and submission of all regulatory documents on behalf of Advaxis to the appropriate health agencies and coordinating joint submissions with Advaxis’s planned partners as warranted. In this role, Mr. Frullo will succeed Ms. Chris L. French, MBA, who will now lead the company’s compliance program.
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The Lm-LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, tregs, and myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. Its lead product ADXS-HPV, an Lm-LLO immunotherapy product candidate used for the treatment of human papilloma virus (HPV) associated cancers, accomplished its Phase II study.
At the end of Thursday’s trade, Canadian Solar Inc. (NASDAQ:CSIQ)‘s shares surged 2.67% to $33.41.
Canadian Solar Inc. (CSIQ) declared that effective June 1, the company has been offering a new upgraded warranty on its polycrystalline photovoltaic modules by guaranteeing a lower first year power output degradation, less than 2.5%. This is in contrast to the industry standard of 3% degradation during the first year.
All Canadian Solar standard modules have a 10-year limited product warranty on material and workmanship. In addition, the following are the new warranty policies related to power performance:
- For polycrystalline module products, Canadian Solar guarantees the first year power degradation is no more than 2.5% from its nameplate power. From year 2 to year 25, the actual power decline will be no more than 0.7%. By the end of year 25, the actual power output will be no less than 80.7% of the nameplate power output.
- For the Diamond double-glass module, Canadian Solar guarantees the first year power degradation is no more than 2.5% from its nameplate power. From year 2 to year 30, the actual annual power decline will be no more than 0.5%. By the end of year 30, the actual power output will be no less than 83% of the labeled power output.
In the past 15 years, Canadian Solar has invested heavily into solar cell and module technology research and development. This warranty upgrade is based on internal and external PV system performance test results.
The performance warranty for standard monocrystalline cell modules will continue to be 3% degradation for the first year, and 0.7% power loss from year 2 to year 25. With Czochralski-type (CZ) wafer quality improvement, Canadian Solar will be able to roll out a similar improved performance warranty for monocrystalline cell modules in the future.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products worldwide. The company operates in two segments, Module and Energy. Its products comprise various solar modules that are used in residential, commercial, and industrial solar power generation systems. The company also provides specialty solar products comprising of Andes Solar Home System, an off-grid solar system, designed to provide an economical source of electricity to homes and communities without access to grid; and Maple Solar System, a clean energy solution for families, in addition to solar system kits, which are a ready-to-install packages, such as inverters, racking system, and other accessories.
MasTec, Inc. (NYSE:MTZ), ended its Thursday’s trading session with 0.21% gain, and closed at $18.91.
MasTec, Inc. (MTZ) declared that its senior administration will be in New York presenting at the Stifel 2015 Industrials Investor Conference on Tuesday, June 16th, at about 1:50 p.m. Eastern time. One-on-one meetings with institutional investors and MasTec’s senior administration are also being arranged as a part of the conference.
MasTec, Inc., an infrastructure construction company, provides engineering, building, installation, maintenance, and upgrade services for energy, utility, and communications infrastructure primarily in the United States. It operates in five segments: Communications, Oil and Gas, Electrical Transmission, Power Generation and Industrial, and Other.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
